Mepolizumab therapy improves the most bothersome symptoms in patients with hypereosinophilic syndrome.

ABSTRACT:

Background

Hypereosinophilic syndrome (HES) is characterized by persistent elevated blood and/or tissue eosinophil levels and eosinophil-mediated organ damage. Presentation is highly heterogenous; patients may experience symptoms affecting multiple organ systems.

Objectives

To assess the effects of mepolizumab, which targets interleukin-5, on HES-related symptom burden, based on HES daily symptoms (HES-DS) questionnaire data collected during the Phase III (ClinicalTrials.gov ID: NCT02836496) study of mepolizumab in patients with HES.

Methods

Each of the six HES-related symptoms were rated (0-10) daily by patients, recalling worst symptom experience in the prior 24 hours; change from baseline at Week 32 was also calculated for mepolizumab versus placebo.

Results

SUBMITTER: Roufosse F 

PROVIDER: S-EPMC10090544 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature